Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes.

Literature DB >> 20975810

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes.

Rolee Pathak¹, Mary Barna Bridgeman.

Abstract

Entities: Disease Gene

Year: 2010 PMID： 20975810 PMCID： PMC2957740

Source DB: PubMed Journal: P T ISSN： 1052-1372

× No keyword cloud information.

18 in total

1. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

Authors: Arthur Bergman; David Ebel; Fang Liu; Julie Stone; Amy Wang; Wei Zeng; Li Chen; Stacy Dilzer; Kenneth Lasseter; Gary Herman; John Wagner; Rajesh Krishna
Journal: Biopharm Drug Dispos Date: 2007-09 Impact factor: 1.627

2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Authors: Bernard Charbonnel; Avraham Karasik; Ji Liu; Mei Wu; Gary Meininger
Journal: Diabetes Care Date: 2006-12 Impact factor: 19.112

3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

Authors: I Raz; M Hanefeld; L Xu; C Caria; D Williams-Herman; H Khatami
Journal: Diabetologia Date: 2006-09-26 Impact factor: 10.122

4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Authors: Julio Rosenstock; Ronald Brazg; Paula J Andryuk; Kaifeng Lu; Peter Stein
Journal: Clin Ther Date: 2006-10 Impact factor: 3.393

Review 5. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.

Authors: Joshua J Neumiller; Lindy Wood; R Keith Campbell
Journal: Pharmacotherapy Date: 2010-05 Impact factor: 4.705

6. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.

Authors: Priscilla Hollander; Jia Li; Elsie Allen; Roland Chen
Journal: J Clin Endocrinol Metab Date: 2009-10-28 Impact factor: 5.958

7. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.

Authors: Elizabeth M Migoya; Catherine H Stevens; Arthur J Bergman; Wen-lin Luo; Kenneth C Lasseter; Stacy C Dilzer; Michael J Davies; John A Wagner; Gary A Herman
Journal: Can J Clin Pharmacol Date: 2009-02-16

Review 8. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Authors: Joshua J Neumiller
Journal: J Am Pharm Assoc (2003) Date: 2009 Sep-Oct

9. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.

Authors: Ralph A DeFronzo; Miguel N Hissa; Alan J Garber; Jorge Luiz Gross; Raina Yuyan Duan; Shoba Ravichandran; Roland S Chen
Journal: Diabetes Care Date: 2009-05-28 Impact factor: 19.112

10. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial.

Authors: A R Chacra; G H Tan; A Apanovitch; S Ravichandran; J List; R Chen
Journal: Int J Clin Pract Date: 2009-07-15 Impact factor: 2.503

25 in total

1. Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers.

Authors: Arun K P; Venkata Subbaiah Meda; V S P Raj Kucherlapati; Anil Dubala; Deepalakshmi M; Anand VijayaKumar P R; Elango K; Suresh B
Journal: Eur J Clin Pharmacol Date: 2011-12-16 Impact factor: 2.953

2. Dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucagon-like peptide (GLP-1) secretion in arsenically safe pigmented red rice (Oryza sativa L.) and its product.

Authors: Duyi Samyor; Danielle Calderwood; Manus Carey; Amit B Das; Brian D Green; Sankar C Deka
Journal: J Food Sci Technol Date: 2022-04-11 Impact factor: 3.117

Review 3. Regulation of glucose homeostasis by GLP-1.

Authors: Prashant Nadkarni; Oleg G Chepurny; George G Holz
Journal: Prog Mol Biol Transl Sci Date: 2014 Impact factor: 3.622

4. Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole.

Authors: Chirag G Patel; Li Li; Suzette Girgis; David M Kornhauser; Ernest U Frevert; David W Boulton
Journal: Clin Pharmacol Date: 2011-06-22

5. Cutaneous manifestations of diabetes mellitus.

Authors: Michelle Duff; Olga Demidova; Stephanie Blackburn; Jay Shubrook
Journal: Clin Diabetes Date: 2015-01

6. Factors associated with utilization of dipeptidyl-4 inhibitors in patients with type 2 diabetes mellitus: a cross-sectional retrospective study.

Authors: Hasniza Zaman Huri; NorFarahen Selamat; Shireene Ratna Vethakkan
Journal: Int J Endocrinol Date: 2014-09-02 Impact factor: 3.257

Review 7. The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect.

Authors: Konstantinos Makrilakis
Journal: Int J Environ Res Public Health Date: 2019-07-30 Impact factor: 3.390